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Introduction: It has been postulated that factor VIII (FVIII) products containing vonWillebrand factor (VWF) may
improve immune tolerance induction (ITI) success rate in patientswith haemophilia A andpoor prognostic factors.
Materials and methods:We conducted a retrospective cohort analysis of a FVIII/VWF concentrate (BIOSTATE®) for
ITI in paediatric patients with severe haemophilia A (SHA) and inhibitors, from January 2003 to December 2011 at
3 paediatric-onlyHaemophilia Treatment Centres inAustralia. Response to ITIwas assessedat or before 33 months
and at completion of ITI. Fifteen male patients with SHA were included in the analysis.
Results: BIOSTATEwas used for primary ITI in 8 patients (2 years, range 1.1–11.5 years) and for salvage ITI in 7 pa-
tients (9.9 years, range 1.1–15.4). At the end of the observation period therewere 11patientswho achieved a com-
plete responsewith BIOSTATE after amedian duration of 21 months (range 5–85 months); a partial responsewas
achieved in 2 patients in whom ITI is ongoing. Therefore, the overall response rate was 86.6%. Two patients were
deemed treatment failures: one due to non-compliance after 18 months of ITI and another in whom a partial re-
sponse had not been achieved after 22 months of ITI.
Conclusion: BIOSTATE was well-tolerated and effective when used for primary or salvage ITI in this cohort of pae-
diatric patients with SHA and a high-level inhibitor.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The availability of factor (F)VIII concentrates for regular prophylactic
administration has dramatically transformed joint outcomes and
long-term prognosis for individuals with severe haemophilia A
(SHA) [1]. Development of FVIII-neutralising alloantibodies (inhibitors)
represents a serious complication, as the haemostatic effect of FVIII re-
placement is greatly diminished or completely abolished. The cumula-
tive incidence of inhibitor development in SHA is ~20–30%; however,; CR, Complete response; CVAD,
ibitor bypassing activity; FVIII,
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venous immunoglobulin; PK,
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in).
. This is an open access article underthemajority of these developwithin theﬁrst 20 exposures to exogenous
FVIII, and the risk is modiﬁed by a number of genetic and treatment-
related factors [2–4]. Haemostasis for patients with high-level inhibitors
(i.e. those with an inhibitor titre N5 Bethesda Units, BU/mL) can only be
achieved using bypassing agents (e.g. recombinant activated factor VII
[rFVIIa] or FVIII inhibitor bypassing activity [FEIBA]). These agents have
an inferior haemostatic effect compared with FVIII replacement in
patients without inhibitors. If the inhibitor cannot be eradicated, such
patients suffer more bleeds and ultimately have poorer joint outcomes
and reduced quality of life. The cost of their treatment is signiﬁcantly
greater than their inhibitor-negative counterparts [5,6].
Immune tolerance induction (ITI), in which regular and frequent in-
fusion of FVIII concentrate over months – or years – is used tomodulate
the immune response, remains the only establishedmethod of inhibitor
eradication [5,7]. The overall success rate for ITI in SHA is ~70%; howe-
ver, the ideal treatment regimen remains the focus of ongoing investiga-
tion, and a variety of approaches have been adopted since the original
(“Bonn”) protocol involving very high doses of FVIII was ﬁrst describedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ITI, and current practice is largely determined by individual clinician
preferences at each haemophilia centre, as well as published consensus
guidelines [5,9,10]. The possibility that the type of FVIII product used for
ITI could inﬂuence the likelihood of successful tolerisation is the subject
of intense debate [11]. In particular it has been postulated that FVIII
products containing von Willebrand factor (VWF) may improve the ITI
success rate in some patients with inhibitors, especially those with
poor prognostic characteristics, i.e., a historical peak inhibitor level
N200 BU/mL, an inhibitor level N10 BU/mL at the start of ITI, age
N5 years, or N24 months between inhibitor detection and start of ITI
[11–14].
BIOSTATE (CSL Behring, Australia) is a double virally inactivated,
plasma-derived concentrate containing human FVIII and VWF complex
(approximate FVIII:VWF activity ratio 1:2). BIOSTATE has been ap-
proved in Australia since 2003 for the treatment and prophylaxis of pa-
tients with haemophilia A and since 2008 for the treatment of von
Willebrand disease. BIOSTATE® is also licensed under other names in-
cluding Voncento®, and Alieviate®. The aim of this retrospective study
was to describe the use of BIOSTATE for ITI in paediatric patients in
Australia with SHA and inhibitors.
Materials and Methods
The Australian Haemophilia Centres Director Organisation (AHCDO)
identiﬁed 6 paediatric-only Haemophilia Treatment Centres (HTCs). All
6 centres were surveyed for inclusion in the study: 3 centres agreed to
participate, 2 centres declined participation because they had no eligible
patients. One centre, which had one subject earmarked for inclusion,
declined participation due to resource constraints; one additional sub-
ject was subsequently identiﬁed but not included in this review due to
treatment at an adult/paediatric centre.
A retrospective observational cohort analysis of BIOSTATE use for ITI
from January 2003 to December 2011 was conducted by the 3 partici-
patingmajor paediatric HTCs. This study was approved by the Research
Ethics Board at each site. No patient included in this study was enrolled
in the international immune tolerance (I-ITI) study [15].
The medical records of paediatric patients (b18 years of age) with a
diagnosis of SHA complicated by FVIII inhibitors who had undergone, or
were continuing, ITI with BIOSTATE were examined. Standardised case
report forms were used to collect data regarding patient demographics,
FVIII genotype, and inhibitor history, including details of inhibitor de-
velopment, previous ITI attempts, BIOSTATE regimen for ITI, clinical
course and outcome. Adverse events (AEs) documented during ITI
with BIOSTATE were rated for their severity and potential causal rela-
tionship to ITI treatment. Details of adjuvant immune therapy used dur-
ing ITI were also documented.
Response to ITI was assessed at or before 33 months (‘Response
at ≤ 33 months’) and at completion of ITI (‘Response at end of
study’). Deﬁnitions used for response were adapted from interna-
tional consensus criteria [9]. Thus, a complete response (CR) was de-
ﬁned as an inhibitor titre of b0.6 BU/mL, with a normal FVIII recovery
(N66% predicted) and/or a normal FVIII half-life (N6 hours); partial
response (PR) was deﬁned as an inhibitor titre of b5 BU/mL with ev-
idence of decreased FVIII:C survival but clinically relevant response
to FVIII (as determined by the treating clinician), and treatment
was considered a failure (F) if CR or PR was not achieved within
the observation period, or ITI was ceased before 33 months due to
other reasons.
Statistical Analysis
Analysis was performed predominantly using descriptive methods.
Numerical data were reported as medians with ranges. Graphs were
produced using GraphPad Prism software (GraphPad Prism, La Jolla,
California, USA).Results
Patient Characteristics
Fifteen patients (all males) with SHA and a high-level inhibitor who
had received BIOSTATE for ITI during the observation period were
enrolled. The baseline characteristics of the cohort are summarised in
Table 1. All but one patient had ≥1 identiﬁable genetic risk factor asso-
ciated with a signiﬁcantly increased risk of inhibitor formation, includ-
ing 7 with a known family history of inhibitors, and 13 with recognised
high-risk mutations (6 intron inversions, 7 multi-domain deletions). In
keeping with historical observations the duration of FVIII exposure
prior to initial inhibitor detectionwas generally short (median 12 expo-
sure days, range 4–16, data not available for 4 patients). Only 3 patients
had received a plasma-derived FVIII concentrate prior to inhibitor de-
tection (recombinant FVIII in 12 patients).
BIOSTATE was used for primary (ﬁrst-line) ITI in 8 patients at a
median age of 2 years (range 1.1–11.5 years). These patients had a gen-
erally favourable risk proﬁle, including 5 patients with no predictors of
poor ITI response, 2 patients with a single poor prognostic factor (inhib-
itor level N10 BU/mL at start of ITI) and only 1 patient with multiple
poor prognostic factors. BIOSTATE was used for salvage (second-line)
ITI in 7 patients (median age 9.9 years, range 1.1–15.4); in this group,
only 1 patient lacked identiﬁable predictors of poor ITI response. Patient
9 received BIOSTATE for primary ITI and salvage ITI on two separate oc-
casions (Table 1).
ITI Regimens
A variety of ITI regimens were utilised across the 3 HTCs, both with
and without adjuvant immunomodulatory therapy (Table 2). A once-
daily, high-dose FVIII regimen was the approach most commonly
employed (median dose 100 IU FVIII/kg daily, range 90–120 IU/kg),
and was utilised in 10 patients (5 for primary ITI). These patients pre-
dominantly had a favourable risk proﬁle, including 4 patients with no
predictors of poor ITI response, and only one patientwith N1 poor prog-
nostic factor. An intensive twice-daily regimen (median dose 100 IU
FVIII/kg bd) was used in 3 patients, all deemed to be at high risk of ITI
failure (2 patients had multiple predictors of poor ITI response; the
other patient was considered high risk because N5 years had elapsed
since the inhibitor was ﬁrst detected, and his historical peak inhibitor
level was unknown). Conversely, a low dose/low frequency three-
times-per-week regimen was adopted as primary ITI in 2 patients (40
and 50 IU FVIII/kg), both of whom had a favourable risk proﬁle (no
poor prognostic factors).
Use of adjuvant immunomodulatory therapy during attempted ITI
was common but highly heterogeneous. Rituximab (monoclonal anti-
CD20 antibody) was the agent utilised most frequently, and was incor-
porated into the ITI regimens of 10 patients. Cycles of rituximab were
administered in doses of 375 mg/m2 weekly for 2–4 consecutive
weeks. The total number and frequency of cycles varied considerably
(median 3 cycles, range 1–14). Other agents used in various doses and
combinations included methylprednisolone, intravenous immunoglob-
ulin (IVIG), vincristine and sirolimus (rapamycin).
Bleeding episodes during ITI were predominantly managed with
bypassing agents until such time that FVIII recovery was considered ad-
equate to permit use of FVIII concentrates. Whilst on ITI, prophylaxis
with a bypassing agent was initiated in 6 patients with a high-level in-
hibitor and a history of frequent bleeding episodes (4 with FEIBA, 2
with rFVIIa).
ITI Outcomes
The responses to ITI during therapy are illustrated in Fig. 1. At the
end of the observation period there were 11 patients (73.3%) who had
been successfully tolerised with BIOSTATE (i.e. achieved CR) after a
Table 1
Baseline patient characteristics at initial detection of inhibitor to start of ITI.














1 Multidomain (exon 7 − 20) N 0.1 − 9.9 117.6 10 5 3328.0 48.0
2 Intron 22 inversion N 1.0 − 1.5 6.6 5 0 30.0 6.0
3 Intron 22 inversion N 1.0 − 1.5 6.2 14 0 170.0 8.0
4 Intron 22 inversion N 1.3 − 1.3 0.5 16 1 140.0 64.0
5 Not available Y 7.2 − 7.2 0.5 − 0 13.0 13.0
6 Not available N 3.7 − 5.3 19.0 14 0 7.6 7.6
7 Intron 22 inversion N 1.1 − 1.1 0.3 16 0 10.5 8.7
8 Multidomain (exon 1 − 3) N 3.1 − 4.4 15.7 − 1 92.0 13.0
9 Multidomain (exon 15 − 20) Y 1.6 − 11.5 118.7 6 0 332.0 224.0
10 Intron 22 inversion − 0.7 − 1.1 4.8 16 2 4.4 6.2
11 Multidomain (exon 1 − 14) Y 2.5 − 2.5 0.1 7 0 59.0 50.0
12 Multidomain (exon 1 − 14) Y 1.2 − 11 117.6 12 7 210.0 2.4
13 Multidomain (exon 15 − 20) Y 1.2 − 1.2 0.0 4 0 4.8 4.8
14 Multidomain (exon 15 − 20) Y 1.0 − 15.4 172.8 − 1 − 6.8
15 Intron 22 inversion Y 3.1 − 10.7 91.2 11 None 10.0 5.0
FHx, family history; ED, exposure days; BU, Bethesda units;− indicates data not available.
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tients inwhom ITI is ongoing achieved PR, bringing the overall response
to 86.6%. This included one patient who initially achieved a PR during
primary ITI (patient 9), but reformed a high-level inhibitor 6 months
following cessation of regular rituximab, and later recommenced
BIOSTATE for salvage ITI. Therewere 2 treatment failures: ITIwas ceased
in one patient after 18 months due to non-compliance, despite initially
achieving a PR at 6 weeks (patient 14); ITI is ongoing for the remaining
patient (patient 1), who has not yet achieved PR after 22 months.
The overall response at 33 months for patients on primary ITI was
87.5% (6 CR, 1 PR). Low-risk patients in this group had a CR rate of
100% (4 patients), whilst the overall response in those with poor prog-
nostic factors was 75% (2 CR, 1 PR, 1 F). Complete responses at
33 months were seen in all 3 patients on salvage ITI with b2 poor prog-
nostic factors. In addition 2 patients on salvage ITI with ≥2 poor prog-
nostic factors achieved PR at 33 months, and ultimately achieved CR
after 85 months (patient 12) and 52 months (patient 15) of ongoing
ITI with BIOSTATE. Inhibitor recurrence was not observed in any of the
11 patients who achieved a CR at completion of ITI (median follow-up
period 1.8 years, range: 0.3–7.2 years).Table 2
BIOSTATE ITI regimen and outcome.





1 100 x2 per day 12 3 −
2 40 x3 per week − − −
3 50 x3 per week − − −
4 100 daily 8 2 IVIG
5 100 daily − − −
6 100 daily − − −
7 100 daily − − −
8 100 daily 8 2 −
9 100 x2 per day 36 10 VCR, Pred,
9‡ 100 x2 per day 8 2 Sirolimus,
10 100 daily 4 1 −
11 100 daily 39 12 Pred, IVIG
12 100 daily 31 14 VCR
13 120 daily 3 1 IVIG, Pred
14 100 x2 per day 20 5 −
15 90 daily 15 4 −
CR, complete response; PR, partial response; F, failed ITI; IVIG, intravenous immunoglobulin; V
2 − 4 standard 375 mg/m2 doses; †Relapsed 6 months after cessation of regular rituximab; ‡Se
pliance); **Ongoing ITI.Adverse Events
Due to the retrospective nature of the study only AEs documented
in patient medical charts were recorded. Central venous access de-
vice (CVAD)-related infection was the most commonly reported
AE, occurring in 5 patients. Multiple episodes of CVAD-related infec-
tion were observed in 3 patients (range 2–4 episodes), one of whom
required CVAD replacement. Other documented AEs included a
blocked CVAD, hypogammaglobulinaemia (1 patient, likely related to
adjuvant immunomodulatory therapy), and infection not related to a
CVAD (4 episodes, 3 patients). Bleeding episodes during ITI were not
well documented in patient records, presumably as most were treated
at home or at medical facilities distant to the primary HTC. No
BIOSTATE-related AEs were reported during the study.
Discussion
ITI using regular infusions of FVIII concentrate is currently the
only established method of inhibitor eradication in patients with
haemophilia A. The potential for VWF to enhance ITI response byune therapy Duration
(Months)









IVIG 35.8 PR† F†







CR, intravenous vincristine; Pred, methylprednisolone; *Cycles of rituximab consisted of
cond course of ITI using BIOSTATE; ¶Relapsed following cessation of ITI therapy (non-com-
Fig. 1. Responses to ITI therapy a) patients undergoing primary ITI b) patients undergoing salvage ITI.
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ously been postulated, and it remains plausible that ITI using VWF-
containing FVIII concentrates may improve success rates in a subset
of patients [8,16–18]. In practice, this hypothesis has been difﬁcult
to test, as product choice for ITI is generally determined by local pref-
erence and opinion at individual HTCs.
In this retrospective, multicentre observational study of Australian
paediatric patients with SHA and high-level inhibitors, the use of a
plasma-derived VWF-containing FVIII concentrate (BIOSTATE) for pri-
mary and salvage ITI was examined. Outcomes were assessed using
criteria derived from those outlined in previously published interna-
tional consensus guidelines, with the exception that 33 months was
not used as a ﬁnal determinant of ITI failure, and formal pharmacokinet-
ic (PK) studieswere not required to establish ITI success [9].Whilst FVIII
recovery data were readily available in most patients on completion of
ITI, comprehensive PK studies were rarely performed – a likely reﬂec-
tion of the cumbersome nature of these assessments.
This represents the ﬁrst study to describe use of BIOSTATE for ITI
(recombinant FVIII products are most commonly selected for this pur-
pose in most Australian HTCs). Although it is not possible to determine
the speciﬁc reasons for which BIOSTATE was chosen in these patients,
the study does highlight the heterogeneity in approach to ITI in
Australia generally, both in terms of patient selection (i.e. who is suit-
able for ITI) and dosing regimen. No particular pattern of patient selec-
tion was apparent: the cohort encompassed a range of ages and risk
proﬁles, including more than half who would not have been eligible
for entry into the I-ITI study due to the presence of one or more
“poor-risk” features [15]. Indeed, recruitment was an issue for the I-ITI
study, as a signiﬁcant number of potential patients did not meet the el-
igibility criteria due to the existence of such risk factors. Nonetheless,
the observed responses in the present study (73.3% CR, 13.3% PR)
were comparable to those described in the I-ITI study (~70% CR, 5%
PR)which used very strict criteria to deﬁne successful tolerance, includ-
ing demonstration of normal FVIII half-life and a somewhat arbitrary
33-month maximum treatment period.
Currently BIOSTATE is the only VWF-containing FVIII concentrate
approved and funded for use in Australia. ITI success rates using severalother FVIII/VWF concentrates have been reported in studies elsewhere
[13,16–23]. Similar to this study, these are predominantly small ret-
rospective chart reviews, and include patients with a range of risk
proﬁles receiving both primary and salvage ITI. The largest of these
cohorts (Kurth et al) was a multicentre US study that included 33 pa-
tients (8 primary ITI) and reported overall response rates of 75% and
52% for primary and secondary ITI, respectively [21]. In addition,
Gringeri et al reported results from a prospective study of ITI outcomes
using a FVIII/VWF concentrate in 17 high-risk patients, in which CR
(53%) or PR (41%)was achieved in all but one patient, including all 4 pa-
tients who had previously failed attempted ITI using a non-VWF con-
taining FVIII concentrate [13]. This is similar to the ﬁndings of the
original Frankfurt study in which 8 of 10 patients who had failed ITI
using a high-purity FVIII concentrate were successfully tolerised when
switched to a VWF-containing product [12]. In contrast, Greninger
et al reported failure in 4 patients who were switched to a FVIII/VWF
concentrate after failing ITI using recombinant FVIII, but success in all
7 patients considered to be at high risk of failure who commenced pri-
mary ITI with a FVIII/VWF concentrate [20].
Taken together these studies support the hypothesis that VWF-
containing FVIII concentrates are effective for both primary and second-
ary ITI in a signiﬁcant proportion of patients, and that previous ITI failure
with a high-purity FVIII concentrate does not consistently predict failure
using a FVIII/VWF concentrate for subsequent ITI attempts. In this
BIOSTATE studypatientswithmultiple risk factors generally took longer
to achieve PR or CR, but ultimately only one patient failed ITI despite
good compliance (patient 1). ITI in this case was complicated by multi-
ple CVAD infections, including one episode requiring CVAD replace-
ment. One other patient who suffered multiple CVAD infections
(patient 11) achieved a PR after 36 months of ITI. It remains unclear
as to whether CVAD infection per se has any effect on tolerisation suc-
cess; notably, although anecdotally CVAD infection has been implicated
as a cause of inhibitor recurrence after successful ITI, the I-ITI study
found no association between CVAD infection and ITI outcome [15,24].
Clearly more research regarding predictors of ITI response is needed.
The I-ITI study compared ITI using a low- versus high-dose FVIII reg-
imen in “good-risk” patients, and demonstrated similar response rates
1050 J.D. Robertson et al. / Thrombosis Research 134 (2014) 1046–1051in both groups, butmore bleeding episodes in the low-dose group in as-
sociation with a longer time to achieve a negative inhibitor titre [15]. In
contrast most patients in the BIOSTATE study were commenced on a
high-dose regimen, predominantly once daily (100 FVIII IU/kg), with
twice-daily dosing (100 FVIII IU/kg bd) used in 3 patients considered
to be at high risk of ITI failure. Low-dose ITI was only adopted in 2 pa-
tients, both N2 years of age and lacking risk factors. Bleeding was not
formally assessed in this study as medical charts were not considered
a reliable indicator of actual bleeding frequency. Anecdotally, treating
clinicians did report an overall reduction in bleeding events, particularly
as inhibitor levels fell below 5 BU/mL, in accordance with observations
from larger studies.
Off-label use of adjuvant immunomodulatory therapy, particularly
rituximab, wasmore common andmore intensive in this Australian co-
hort compared with previous studies. The role of such potent immune
suppressants in ITI remains undeﬁned; although rituximab is associated
with amore rapid decline in inhibitor level, it is not establishedwhether
this translates into better clinical outcomes (i.e. less bleeding, and great-
er chance of ITI success) [25]. Furthermore, serious – sometimes fatal –
AEs occur in a small proportion of patients who receive rituximab, and
the safety of long-term effects of regular rituximab administration in
ITI has not been examined. Also the long-term effects of regular rituxi-
mab on immune function are not known. In this study, one patient (pa-
tient 9) had recurrence of a high-level inhibitor 6 months after ceasing
regular rituximab, despite continuing high-dose ITI with BIOSTATE
throughout this period. The rising inhibitor was associated with a
marked increase in bleeding symptoms, including an intracranial haem-
orrhage. Following a prolonged interruption to ITI (to allow the inhibi-
tor level to fall) this patient recommenced regular rituximab with
salvage ITI, and rapidly achieved PRwith a corresponding improvement
in bleeding frequency. In other patients, the response to rituximab was
not as readily apparent, including one patient in whom the agent ap-
peared to have no effect on inhibitor level, despite laboratory conﬁrma-
tion of complete B-cell depletion (patient 1).
There are several important limitations of this study that must be
taken into account when comparing the outcomes with ITI in other
cohorts. As a retrospective and purely descriptive observational
study, no ﬁrm conclusions can be drawn regarding the efﬁcacy of
BIOSTATE relative to other FVIII concentrates (plasma-derived or re-
combinant) used for ITI. Data such as bleeding episodes, AEs and ITI
compliance were difﬁcult to ascertain frommedical charts, and likely
to be under-reported. Factor levels and inhibitor assays were per-
formed at local laboratories associated with each HTC and therefore
not necessarily equivalent. Deﬁnitions of response were not as strict
as those used in the I-ITI study, partly because the relevant data were
not available, but also because therewas a lack of consensus between
HTCs as to what should constitute ITI success or failure. Interpreta-
tion of outcomes was further complicated by the frequent use of
immunomodulatory agents, the heterogeneous nature of the popu-
lation risk factors and ITI regimens, and the unknown impact these
may have had on ITI success.Conclusions
The FVIII/VWF concentrate BIOSTATE appeared to be well-tolerated,
safe and effective when used for primary or salvage ITI in this cohort of
paediatric patients with SHA and a high-level inhibitor. Despite the
presence of poor prognostic factors inmore than half these patients, ob-
served success rates were similar to those previously reported in other
ITI studies. Rituximab was frequently utilised as an adjuvant immuno-
modulatory agent in this cohort, although its exact role in ITI remains
unclear, and the safety of prolonged administration has not been exam-
ined. Further research iswarranted, particularly in the subset of patients
withmultiple risk factors and frequent bleeding for whom the results of
the I-ITI study are not directly applicable.Conﬂict of Interest Statement
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